Nasdaq · Healthcare
QuidelOrtho Corp (QDEL)
As-reported financials and recent SEC filings for QuidelOrtho Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.73B
Net income
$-1.13B
Net margin
-41.5%
Diluted EPS
$-16.69
ROE
7349.4%
P/E (TTM)
—
Market cap
$940.4M
Debt / equity
-160.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $2.73B | $2.78B | $3.00B | $3.27B | $1.70B |
| Gross profit | — | — | — | — | — |
| Operating income | $-919.2M | $-1.96B | $139.1M | $843.7M | $906.0M |
| Net income | $-1.13B | $-2.05B | $-10.1M | $548.7M | $704.2M |
| Diluted EPS | $-16.69 | $-30.54 | $-0.15 | $9.56 | $16.43 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-23
View on EDGAR →8-K2026-06-16
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →Go deeper on QDEL
Search QuidelOrtho Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.